(MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

47. The use according to any one of claims 37 to 46, the CD22 antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.

48. The use according to any one of claims 37 to 47, wherein the CD22 antibody-drug conjugate is anti-CD22-MC-vc-PAB-MMAE.

49. The use according to any one of claims 37 to 48, wherein the anti-CD22 antibody in said CD22 antibody-drug conjugate is 10F4.v3.

50. The use according to any one of claims 37 to 49, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.

~~51. The invention as herein before described.~~